{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:29:50Z","timestamp":1793813390044,"version":"4.6.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101132946"],"award-info":[{"award-number":["101132946"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101132901"],"award-info":[{"award-number":["101132901"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhepr.2026.101957","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:06:51Z","timestamp":1783782411000},"page":"101957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The use of FGF21 analogues in MASH and MASH cirrhosis \u2013 metabolic master regulators or liver-specific mechanisms?"],"prefix":"10.1016","volume":"8","author":[{"given":"A.G.","family":"Holleboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101957_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101957_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101957_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101957_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101957_bib5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101957_bib8","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101957_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101957_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.jhepr.2026.101957_bib11","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"issue":"0","key":"10.1016\/j.jhepr.2026.101957_bib12","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"0","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101957_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101957_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2017.12.001","article-title":"A critical review of endpoints for non-cirrhotic NASH therapeutic trials","volume":"68","author":"Ratziu","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101957_bib16","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib17","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101957_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/lt.25003","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"24","author":"Younossi","year":"2018","journal-title":"Liver Transpl"},{"issue":"S1","key":"10.1016\/j.jhepr.2026.101957_bib19","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.jhepr.2026.101957_bib20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101957_bib21","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","author":"Driessen","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101957_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.13793","article-title":"MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials","volume":"296","author":"Zannad","year":"2024","journal-title":"J Intern Med"},{"issue":"14\u201315","key":"10.1016\/j.jhepr.2026.101957_bib23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/14656566.2025.2566258","article-title":"Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs","volume":"26","author":"Kaya","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jhepr.2026.101957_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100424","article-title":"Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus","volume":"28","author":"Holleboom","year":"2025","journal-title":"Metab Open"},{"key":"10.1016\/j.jhepr.2026.101957_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101957_bib26","article-title":"Why do so many NASH trials fail?","volume":"18","author":"Ratziu","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","article-title":"The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists","volume":"34","author":"Alkhouri","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cel Metab"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101957_bib32","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.jhepr.2026.101957_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101957_bib35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cel Metab"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101957_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","article-title":"Going back to the biology of FGF21: new insights","volume":"30","author":"Lewis","year":"2019","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101957_bib37","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101957_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jhepr.2026.101957_bib39","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101957_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.semcdb.2015.09.021","article-title":"Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis","volume":"53","author":"Markan","year":"2016","journal-title":"Semin Cel Dev Biol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101957_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molmet.2016.11.001","article-title":"Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates","volume":"6","author":"Lundsgaard","year":"2017","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101957_bib43","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cel Metab"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101957_bib44","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101957_bib45","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2026.101957_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.12688\/f1000research.14117.1","article-title":"Defining \u201cFGF21 Resistance\u201d during obesity: controversy, criteria and unresolved questions","volume":"7","author":"Markan","year":"2018","journal-title":"F1000Research"},{"issue":"18","key":"10.1016\/j.jhepr.2026.101957_bib47","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cel Metab"},{"issue":"37","key":"10.1016\/j.jhepr.2026.101957_bib49","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101957_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049977","article-title":"FGF21 requires \u03b2klotho to act in vivo","volume":"7","author":"Adams","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101957_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cel Metab"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101957_bib52","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101957_bib53","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1210\/en.2013-1191","article-title":"Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice","volume":"154","author":"Camporez","year":"2013","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101957_bib54","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"Owen","year":"2014","journal-title":"Cel Metab"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101957_bib55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3249","article-title":"FGF21 regulates metabolism and circadian behavior by acting on the nervous system","volume":"19","author":"Bookout","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101957_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101564","article-title":"Pharmacological FGF21 signals to glutamatergic neurons to enhance leptin action and lower body weight during obesity","volume":"64","author":"Claflin","year":"2022","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101957_bib57","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.cmet.2025.05.011","article-title":"FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression","volume":"37","author":"Gliniak","year":"2025","journal-title":"Cel Metab"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101957_bib59","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101957_bib61","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101957_bib62","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101957_bib63","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101957_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cel Metab"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101957_bib65","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cel Metab"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101957_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cel Metab"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101957_bib68","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101957_bib69","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101957_bib70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101957_bib71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101957_bib72","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101957_bib73","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10530","key":"10.1016\/j.jhepr.2026.101957_bib74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(25)02276-7","article-title":"Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"407","author":"Noureddin","year":"2026","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101957_bib75","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:40:53Z","timestamp":1793810453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589555926002284"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101957","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of FGF21 analogues in MASH and MASH cirrhosis \u2013 metabolic master regulators or liver-specific mechanisms?","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101957"}}